Key result
TYK2 promoter variant is linked to ~4.1-fold higher odds of low fasting insulin in T2D.
Observational (n=173)
Answers are grounded in this paper and cite their sources.
Shows that a TYK2 variant impairs insulin secretion in nonobese type 2 diabetes patients, suggesting viral influences on diabetes risk.
Background: Type 2 diabetes mellitus is typically associated with obesity and insulin resistance. It is well known that viral infection triggers type 1 diabetes, but a potential link with type 2 diabetes has not been fully established. We have reported that a natural mutation in the tyrosine kinase 2 (TYK2) gene, which encodes an interferon receptor signaling molecule, is responsible for encephalomyocarditis (EMC) virus-induced diabetes in mice (Nat Commun 2015). Moreover, a human TYK2 promoter variant (TYK2PV) (NCBI ClinVer ID:440728) is associated with higher risks of not only type 1, but also type 2 diabetes (EBioMedicine 2015). Therefore, we hypothesized that impaired insulin secretion associated with TYK2PV causes type 2 diabetes. Here, we studied the relationships between TYK2PV, and insulin secretion and obesity in patients with type 2 diabetes. Methods: The presence of TYK2PV was determined using direct sequencing, and insulin secretion was evaluated, in type 2 diabetes patients who were not administering either sulfonylureas or insulin. Results: Of the 173 patients assessed, 18 (10.4%) were TYK2PV-positive, and their median BMI was significantly lower than those without the variant (25.3 vs. 23.4 kg/m2, p=0.029). Moreover, the HOMA-β (19.1 vs. 30.0, p=0.027) and fasting serum insulin (3.91 vs. 6.16 μIU/mL, p=0.007) were lower in patients with TYK2PV than in those without. Multivariable analysis showed that TYK2PV was significantly associated with fasting insulin <5μIU/ml (odds ratio 4.14, 95% confidence interval 1.404-12.21, p=0.021). Conclusions: TYK2PV is associated with lower insulin secretion in type 2 diabetes, consistent with it being a virus-induced diabetes susceptibility gene. Therefore, type 2 diabetes patients with TYK2PV should be carefully followed, so that they receive the most appropriate treatment, including insulin.
No takes yet. Share an insight, caveat, or question.
Mori et al. (2019) conducted an observational in Type 2 diabetes (n=173). TYK2 promoter variant (TYK2PV) vs. Patients without the TYK2PV variant was evaluated on Fasting insulin <5μIU/ml (OR 4.14, 95% CI 1.404-12.21, p=0.021). The TYK2 promoter variant (TYK2PV) was significantly associated with fasting insulin <5μIU/ml in patients with type 2 diabetes (OR 4.14; 95% CI 1.404-12.21; P=0.021).
Synapse has enriched 10 related papers. Consider them for comparative context: